Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Experimental group:Lianhua Qingwen capsule
Control group:Placebo
Sponsors
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients with asymptomatic infection of the new coronavirus pneumonia found in accordance with the ''New Coronary Virus Pneumonia Diagnosis and Treatment Program (Trial Version 9)'' and detected by etiological testing. 2. Aged >=18 years, no gender limit. 3. Voluntarily signed a written informed consent before the start of the study.
Exclusion criteria
Exclusion criteria: 1. Mild, normal, severe and critically ill patients with novel coronavirus pneumonia confirmed by etiological tests and clinical manifestations or signs. 2. According to the judgment of the researchers, patients with serious diseases such as malignant diseases, autoimmune diseases, liver and kidney diseases, blood diseases, nervous system diseases, and endocrine system diseases may affect the patients' participation in the trial or the outcome of the study. 3. Patients who are pregnant or breastfeeding. 4. Patients who have participated in other clinical studies within the last 3 months. 5. Allergic constitution, such as allergic history of two or more drugs or food, or known allergy to the ingredients of this medicine. 6. The investigator determined that there were any factors that were not suitable for inclusion or that affected the efficacy evaluation of the patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nucleic acid negative conversion time and negative conversion rate during the isolation observation period; | — |
Countries
China
Contacts
Public ContactNing Guang
Outcome results
None listed